Take an artificial intelligence. Feed it tons of medical and pharmaceutical data, add a good dose of scientific advice, and you may get, like Peter Richardson, a lead to relieve Covid-19 patients.
“Got it! »
It may be less classy than en “Eureka,” but that’s how British pharmacologist Peter Richardson would have punctuated his find – or rather, that of his artificial intelligence – last January. The scientist had indeed alerted l’envisage himself early on to the progress of the Covid-19 even before it was considered a pandemic. Rather than sit idly by, he used artificial l’a intelligence, fed it up with pharmaceutical industry data and medical research, and identified a remedy that could relieve the heaviest lourds symptoms of coronavirus. Easy peasy.
A new way of working
This advance was made possible by Peter Richardson’s employer, BenevolentAI,who developed the artificial intelligence in question. Wired reveals that the teams have published two scientific papers that have caught the attention of Eli Lilly Laboratories, which produce the drug in question, usually used against arthritis. The company announced it is working with the US National Institute of Allergy and Infectious Diseases on clinical trials. For Eli Lilly’s boss, Patrik Jonsson, “the Covid-19 will impact the way we work in many ways.”
It’s true that entrust to the I. A.The task of linking existing treatments to new pathologies is quite new. By Patrik Jonsson’s own admission, the situation is unprecedented: the rapid progression of the pandemic disrupts the time between discoveries and clinical trials. “I can’t guarantee that this treatment will work,” he admits.. But there is a huge need that needs to be addressed now. »
The I. A. at the service of pharma
The Wired article recalls that since the 1950s,the time required to develop new treatments has increased considerably as a result of regulations. A situation that highlights en the valuable assets of artificial intelligence which, in some cases, can greatly shorten these delays.
In fact,in Silicon Valley, partnerships between pharma and tech are legion: Lilly and Pfizer are working with Atomwise, which uses machine learning to find new treatments. For its part, BenevolentAI is working with Novartis on the treatment of cancers and AstraZeneca on kidneydisease.
Of course, it is not a question of relying solely on the recommendations of artificial intelligence to get out of the crisis.. Patrik Jonsson also stresses the need for clinical trials and caution, especially as a new virus could lead to new side effects.
In the end,we can rejoice in the speed of calculation of the I.A… but we do not forget the precautions of use for all that..